We are live on
!
Find out more
Victory Capital Management Portfolio holdings
AUM
$156B
1-Year Est. Return
27.51%
This Fund
S&P 500
This Quarter
Est. Return
+5.54%
1 Year Est. Return
+27.51%
3 Year Est. Return
+75.53%
5 Year Est. Return
+102.92%
10 Year Est. Return
+480.97%
AUM
$49.6B
AUM Growth
+$5.62B
(+13%)
Cap. Flow
+$2.56B
Cap. Flow
% of AUM
5.15%
Top 10 Holdings %
Top 10 Hldgs %
6.81%
Holding
1,885
New
111
Increased
738
Reduced
863
Closed
63
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Goldman Sachs ActiveBeta US Large Cap Equity ETF
GSLC
|
+$178M |
| 2 |
Schwab Fundamental International Large Company Index ETF
FNDF
|
+$161M |
| 3 |
KLA
KLAC
|
+$151M |
| 4 |
Zions Bancorporation
ZION
|
+$148M |
| 5 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$131M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ingredion
INGR
|
+$85.6M |
| 2 |
Keysight
KEYS
|
+$83.3M |
| 3 |
ATI
ATI
|
+$81.4M |
| 4 |
Kennametal
KMT
|
+$66.6M |
| 5 |
Keurig Dr Pepper
KDP
|
+$65.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.46% |
| 2 | Industrials | 15.08% |
| 3 | Technology | 14.03% |
| 4 | Consumer Discretionary | 11.15% |
| 5 | Healthcare | 8.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
926
Equifax
EFX
$20.8B
| $3.99M | 0.01% |
29,529
-50
| -0.2% | -$6.27K |
|
927
Cigna
CI
$71.5B
| $3.99M | 0.01% |
25,345
+1,214
| +5% | +$190K |
|
928
Boston Scientific
BSX
$69.2B
| $3.99M | 0.01% |
92,885
-4,744
| -5% | -$182K |
|
|
LTHM
929
DELISTED
Livent Corporation
LTHM
| $3.99M | 0.01% |
576,289
-1,558,473
| -73% | -$14M |
|
|
THS
930
DELISTED
Treehouse Foods
THS
| $3.99M | 0.01% |
+73,680
| New | +$4.3M |
|
931
Goldman Sachs
GS
$309B
| $3.98M | 0.01% |
19,478
-999
| -5% | -$198K |
|
932
F5
FFIV
$23.4B
| $3.97M | 0.01% |
27,239
+6,268
| +30% | +$938K |
|
933
Charter Communications
CHTR
$18.3B
| $3.91M | 0.01% |
9,887
-501
| -5% | -$188K |
|
934
Lincoln Electric
LECO
$15.2B
| $3.88M | 0.01% |
47,163
+7,704
| +20% | +$641K |
|
935
Dolby
DLB
$5.75B
| $3.87M | 0.01% |
59,847
+144
| +0.2% | +$9.18K |
|
936
Rollins
ROL
$18.1B
| $3.83M | 0.01% |
160,340
+2,003
| +1% | +$51.6K |
|
937
Constellation Brands
STZ
$22.3B
| $3.78M | 0.01% |
19,195
-1,050
| -5% | -$205K |
|
938
BOK Financial
BOKF
$8.78B
| $3.78M | 0.01% |
50,070
+7,450
| +17% | +$604K |
|
939
Bruker
BRKR
$7.99B
| $3.74M | 0.01% |
74,884
+148
| +0.2% | +$6.24K |
|
940
Eli Lilly
LLY
$1.04T
| $3.74M | 0.01% |
33,761
-44,829
| -57% | -$5.28M |
|
941
Welltower
WELL
$171B
| $3.69M | 0.01% |
45,263
+4,286
| +10% | +$337K |
|
|
WBT
942
DELISTED
Welbilt, Inc.
WBT
| $3.69M | 0.01% |
220,964
+206,444
| +1,422% | +$3.38M |
|
943
Gen Digital
GEN
$16.7B
| $3.67M | 0.01% |
168,785
+23,373
| +16% | +$502K |
|
944
Herbalife
HLF
$1.31B
| $3.65M | 0.01% |
85,425
-635
| -0.7% | -$30.1K |
|
945
TransDigm Group
TDG
$69.4B
| $3.63M | 0.01% |
7,496
+47
| +0.6% | +$22K |
|
946
Sabre
SABR
$838M
| $3.61M | 0.01% |
162,572
+24,399
| +18% | +$523K |
|
947
Southwest Airlines
LUV
$23.9B
| $3.6M | 0.01% |
70,799
-201,072
| -74% | -$10.4M |
|
|
ANSS
948
DELISTED
Ansys
ANSS
| $3.57M | 0.01% |
17,433
+52
| +0.3% | +$9.91K |
|
949
Tyler Technologies
TYL
$12.6B
| $3.56M | 0.01% |
16,475
+18
| +0.1% | +$3.9K |
|
|
KZR
950
DELISTED
Kezar Life Sciences
KZR
| $3.56M | 0.01% |
46,145
+23,711
| +106% | +$3.69M |
|
Similar funds
Victory Capital Management's Q2 2019 Portfolio in Review
As of Q2 2019, Victory Capital Management held 1,885 positions worth $49.6B, up 13% from $44B the previous quarter. Its ten largest holdings account for 6.8% of the portfolio.
Victory Capital Management deployed $2.56B of net new capital in Q2 2019, opening 111 new positions and adding to 738 existing holdings. Its largest new stake was Goldman Sachs ActiveBeta US Large Cap Equity ETF: 3,081,520 shares worth $181M.
By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 17% a quarter earlier, followed by Industrials and Technology.
On the sell side, the largest reduction was Ingredion, an estimated $85.6M trimmed.
- Victory Capital Management's largest Q2 2019 buy was Goldman Sachs ActiveBeta US Large Cap Equity ETF: 3,081,520 shares worth $181M.
- Victory Capital Management added most to KLA in Q2 2019, an estimated $151M increase.
- Victory Capital Management's biggest Q2 2019 reduction was Ingredion, cutting an estimated $85.6M.
- Victory Capital Management fully exited Teladoc Health in Q2 2019, selling an estimated $50.5M.
- Victory Capital Management's ten largest holdings make up 6.8% of its $49.6B portfolio in Q2 2019.
- Victory Capital Management opened 111 new positions and closed 63 in Q2 2019.
- Victory Capital Management's portfolio value rose 13% quarter-over-quarter to $49.6B.
Based on Victory Capital Management's 13F filing for Q2 2019, filed 15 Aug 2019.